These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 8067599)

  • 1. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of superoxide.
    Eda R; Townley RG; Hopp RJ
    Ann Allergy; 1994 Aug; 73(2):154-60. PubMed ID: 8067599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of terfenadine on neutrophil and eosinophil chemotactic activities after inhalation of platelet-activating factor in vivo and on neutrophil chemotaxis in vitro.
    Okada C; Hopp RJ; Miyagawa H; Sugiyama H; Nair NM; Bewtra AK; Townley RG
    Int Arch Allergy Immunol; 1992; 97(3):181-6. PubMed ID: 1587633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of platelet-activating factor on superoxide anion production in human eosinophils and neutrophils.
    Mabuchi K; Sugiura T; Ojima-Uchiyama A; Masuzawa Y; Waku K
    Biochem Int; 1992 May; 26(6):1105-13. PubMed ID: 1321621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PAF, FMLP and opsonized zymosan on the release of ECP, elastase and superoxide from human granulocytes.
    Turner NC; Wood LJ; Foster M; Gueremy T
    Eur Respir J; 1994 May; 7(5):934-40. PubMed ID: 8050551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release.
    Moy JN; Gleich GJ; Thomas LL
    J Immunol; 1990 Oct; 145(8):2626-32. PubMed ID: 2170521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of loratadine on human eosinophil function in vitro.
    Eda R; Sugiyama H; Hopp RJ; Bewtra AK; Townley RG
    Ann Allergy; 1993 Oct; 71(4):373-8. PubMed ID: 8214802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of degranulation from human eosinophils by platelet-activating factor.
    Kroegel C; Yukawa T; Dent G; Venge P; Chung KF; Barnes PJ
    J Immunol; 1989 May; 142(10):3518-26. PubMed ID: 2541198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of glucocorticoids on rat eosinophil superoxide generation and chemotaxis.
    Sugimoto Y; Ogawa M; Tai N; Kamei C
    Int Immunopharmacol; 2003 Jun; 3(6):845-52. PubMed ID: 12781701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of platelet-activating factor in endotoxin-induced priming of rabbit polymorphonuclear leukocytes.
    Stewart AG; Harris T
    J Lipid Mediat; 1991; 3(2):125-38. PubMed ID: 1665713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation.
    Eda R; Sugiyama H; Hopp RJ; Okada C; Bewtra AK; Townley RG
    Int Arch Allergy Immunol; 1993; 102(4):391-8. PubMed ID: 8241801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate.
    el-Shazly AE; Masuyama K; Samejima Y; Eura M; Ishikawa T
    Immunopharmacol Immunotoxicol; 1996 Nov; 18(4):587-95. PubMed ID: 8933171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones.
    Harvath L; Yancey KB; Katz SI
    J Immunol; 1986 Aug; 137(4):1305-11. PubMed ID: 3016092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor.
    Tomioka K; MacGlashan DW; Lichtenstein LM; Bochner BS; Schleimer RP
    J Immunol; 1993 Nov; 151(9):4989-97. PubMed ID: 8409452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistency and pathway of isoflurane-induced inhibition of superoxide production by neutrophils.
    Saad MM; Eom W; Hu G; Kim SJ; Crystal GJ
    Can J Anaesth; 2010 Jan; 57(1):50-7. PubMed ID: 19882198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of an ECF-A and formyl methionyl chemotactic peptides on oxidative metabolism of human eosinophils and neutrophils.
    Beswick PH; Kay AB
    Clin Exp Immunol; 1981 Feb; 43(2):399-407. PubMed ID: 6268337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies indicate that platelet-activating factor is a relatively weak eosinophilotactic mediator.
    Erger RA; Casale TB
    Am J Respir Cell Mol Biol; 1995 Jan; 12(1):65-70. PubMed ID: 7811471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming of neutrophil oxidative responses by platelet-activating factor.
    Gay JC
    J Lipid Mediat; 1990; 2 Suppl():S161-75. PubMed ID: 1966814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro.
    Shindo K; Koide K; Fukumura M
    Biochem Biophys Res Commun; 1997 Aug; 237(1):146-51. PubMed ID: 9266847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition by phenytoin of chemotactic factor - stimulated neutrophil functions.
    Webster RO; Goldstein IM; Flick MR
    J Lab Clin Med; 1984 Jan; 103(1):22-33. PubMed ID: 6317777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthreshold concentrations of anti-proteinase 3 antibodies (c-ANCA) specifically prime human neutrophils for fMLP-induced leukotriene synthesis and chemotaxis.
    Hattar K; Sibelius U; Bickenbach A; Csernok E; Seeger W; Grimminger F
    J Leukoc Biol; 2001 Jan; 69(1):89-97. PubMed ID: 11200073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.